Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 11;10(10):e30723.
doi: 10.1016/j.heliyon.2024.e30723. eCollection 2024 May 30.

Current landscape and support for practical initiation of oncological prehabilitation translatable to thyroid cancer: A position paper

S Jack  1 , E Andritsch  2 , A Joaquim  3 , M C Kreissl  4 , L Locati  5   6 , R T Netea-Maier  7 , J L Reverter  8 , R Elisei  9
Affiliations
Review

Current landscape and support for practical initiation of oncological prehabilitation translatable to thyroid cancer: A position paper

S Jack et al. Heliyon. .

Abstract

Despite a growing body of evidence for the effectiveness of prehabilitation, the uptake of prehabilitation in Europe remains low. Contributing factors range from limited awareness and understanding of prehabilitation to a lack of supporting infrastructure and reimbursement challenges. In this position paper, the authors propose a new comprehensive definition of prehabilitation and identify differentiated thyroid cancer as a type of cancer particularly well-suited for prehabilitation. To support clinicians with the implementation of prehabilitation programs in their clinics, the authors discuss the following practical solutions: a) find the most appropriate prehabilitation program for each patient; b) raise awareness among peers; c) develop evidence to demonstrate the effectiveness of prehabilitation; d) expand the interdisciplinary team; e) expand your network and make use of existing assets; f) utilize learnings from the COVID-19 pandemic.

Keywords: Differentiated thyroid cancer; Oncological prehabilitation.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Rossella Elisei reports financial support was provided by 10.13039/501100003769Eisai Europe Ltd. Rossella Elisei reports a relationship with Eisai Inc that includes: consulting or advisory. Rossella Elisei reports a relationship with Ipsen that includes: consulting or advisory. Rossella Elisei reports a relationship with Bayer that includes: consulting or advisory. Rossella Elisei reports a relationship with Lilly that includes: consulting or advisory. Rossella Elisei reports a relationship with Roche that includes: consulting or advisory. J.L. Reverter reports a relationship with Eisai Inc that includes: consulting or advisory. R.T. Netea-Maier reports a relationship with Eisai Inc that includes: consulting or advisory. L. Locati reports a relationship with 10.13039/501100003769Eisai Inc that includes: consulting or advisory, funding grants, and speaking and lecture fees. L. Locati reports a relationship with MSD that includes: consulting or advisory, funding grants, and speaking and lecture fees. L. Locati reports a relationship with 10.13039/100004334Merck Serono that includes: consulting or advisory and speaking and lecture fees. L. Locati reports a relationship with Lilly that includes: consulting or advisory and speaking and lecture fees. L. Locati reports a relationship with 10.13039/100004339Sanofi that includes: consulting or advisory and speaking and lecture fees. L. Locati reports a relationship with Sun Pharmaceutical Industries Ltd that includes: consulting or advisory and speaking and lecture fees. L. Locati reports a relationship with 10.13039/501100014382Ipsen that includes: consulting or advisory and speaking and lecture fees. L. Locati reports a relationship with 10.13039/100004326Bayer that includes: consulting or advisory and speaking and lecture fees. L. Locati reports a relationship with 10.13039/100004337Roche that includes: consulting or advisory and speaking and lecture fees. L. Locati reports a relationship with Instituto Gentili Srl that includes: consulting or advisory and speaking and lecture fees. L. Locati reports a relationship with New Bridge that includes: consulting or advisory and speaking and lecture fees. E. Andritsch reports a relationship with Eisai Inc that includes: consulting or advisory. A. Joaquim reports a relationship with Bristol Myers Squibb that includes: consulting or advisory. A. Joaquim reports a relationship with 10.13039/501100003769Eisai Inc that includes: consulting or advisory and speaking and lecture fees. A. Joaquim reports a relationship with 10.13039/100004334Merck that includes: consulting or advisory and speaking and lecture fees. A. Joaquim reports a relationship with MSD that includes: consulting or advisory and speaking and lecture fees. A. Joaquim reports a relationship with Novartis that includes: consulting or advisory. A. Joaquim reports a relationship with 10.13039/100004319Pfizer that includes: consulting or advisory and speaking and lecture fees. A. Joaquim reports a relationship with Roche that includes: consulting or advisory. A. Joaquim reports a relationship with Daiichi Sankyo Inc that includes: speaking and lecture fees. A. Joaquim reports a relationship with Gillead that includes: speaking and lecture fees. A. Joaquim reports a relationship with 10.13039/100004330GlaxoSmithKline Inc that includes: speaking and lecture fees. A. Joaquim reports a relationship with Lilly that includes: speaking and lecture fees. A. Joaquim reports a relationship with 10.13039/501100006484Vifor Pharma that includes: speaking and lecture fees. M.C. Kreissl reports a relationship with 10.13039/100004326Bayer Healthcare that includes: consulting or advisory and speaking and lecture fees. M.C. Kreissl reports a relationship with 10.13039/501100003769Eisai Inc that includes: consulting or advisory and speaking and lecture fees. M.C. Kreissl reports a relationship with 10.13039/100010544Exelixis that includes: consulting or advisory and funding grants. M.C. Kreissl reports a relationship with Factfield that includes: consulting or advisory. M.C. Kreissl reports a relationship with 10.13039/100004313General Electric that includes: consulting or advisory, funding grants, and speaking and lecture fees. M.C. Kreissl reports a relationship with 10.13039/501100014382Ipsen that includes: consulting or advisory and speaking and lecture fees. M.C. Kreissl reports a relationship with Liam GmbH that includes: consulting or advisory. M.C. Kreissl reports a relationship with Lilly that includes: consulting or advisory. M.C. Kreissl reports a relationship with 10.13039/100004336Novartis that includes: consulting or advisory and speaking and lecture fees. M.C. Kreissl reports a relationship with Onkowissen Gmbh that includes: consulting or advisory. M.C. Kreissl reports a relationship with Pfizer that includes: consulting or advisory. M.C. Kreissl reports a relationship with Roche that includes: consulting or advisory. M.C. Kreissl reports a relationship with 10.13039/100013995Sanofi Genzyme that includes: consulting or advisory, funding grants, and speaking and lecture fees. M.C. Kreissl reports a relationship with Sirtex that includes: consulting or advisory, funding grants, and speaking and lecture fees. M.C. Kreissl reports a relationship with Takeda that includes: consulting or advisory. M.C. Kreissl reports a relationship with Thieme Publishing that includes: consulting or advisory. M.C. Kreissl reports a relationship with ITM that includes: funding grants and speaking and lecture fees. M.C. Kreissl reports a relationship with Tanaka that includes: speaking and lecture fees. M.C. Kreissl reports a relationship with 10.13039/501100004830Siemens that includes: speaking and lecture fees. M.C. Kreissl reports a relationship with Curium that includes: speaking and lecture fees. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Image 1
Graphical abstract
Fig. 1
Fig. 1
Examples of prehabilitation interventions.
See this image and copyright information in PMC

References

    1. Rengel K.F., Mehdiratta N., Vanston S.W., Archer K.R., Jackson J.C., Thompson J.L., Pandharipande P.P., Hughes C.G. A randomised pilot trial of combined cognitive and physical exercise prehabilitation to improve outcomes in surgical patients. Br. J. Anaesth. 2021;126(2):e55–e57. doi: 10.1016/j.bja.2020.11.004. - DOI - PMC - PubMed
    1. Silver J.K., Baima J. Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am. J. Phys. Med. Rehabil. 2013;92(8):715–727. doi: 10.1097/PHM.0b013e31829b4afe. - DOI - PubMed
    1. Santa Mina D., van Rooijen S.J., Minnella E.M., Alibhai S.M.H., Brahmbhatt P., Dalton S.O., Gillis C., Grocott M.P.W., Howell D., Randall I.M., Sabiston C.M., Silver J.K., Slooter G., West M., Jack S., Carli F. Multiphasic prehabilitation across the cancer continuum: a narrative review and conceptual framework. Front. Oncol. 2021;10 doi: 10.3389/fonc.2020.598425. - DOI - PMC - PubMed
    1. Durrand J., Singh S.J., Danjoux G. Prehabilitation. Clin. Med. 2019;19(6):458–464. doi: 10.7861/clinmed.2019-0257. - DOI - PMC - PubMed
    1. Silver J.K. Prehabilitation could save lives in a pandemic. BMJ. 2020;369 doi: 10.1136/bmj.m1386. - DOI - PubMed

LinkOut - more resources